RBC analyst Conor McNamara told CNBC the wait might be a little longer.
Get this delivered to your inbox, and more info about our products and services.
The bank pointed to recent M&A success as a catalyst for the stock.
RBC's $22 price target implies an upside of 74% for shares of Biohaven.
Carter Worth breaks down the charts on this biotech stock.
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of…
Frank Cappelleri of CappThesis breaks down the bullish technical backdrop for this pharma-related stock.
Chart analyst Frank Cappelleri breaks down the technical outlook on the biotech stock.
